PARIS Drugmakers Sanofi and Regeneron said on Saturday results from a one-year test of their Dupixent product aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD) had been positive. <\/p>\n
\"In the CHRONOS study, Dupixent used with topical corticosteroids showed significantly greater clearance of skin lesions and overall disease severity compared to topical corticosteroids alone, which are commonly prescribed for moderate-to-severe atopic dermatitis,\" Andrew Blauvelt, the principal investigator of the study, said in a joint statement from the companies. <\/p>\n
\"This study provides positive long-term data for Dupixent, which is important given atopic dermatitis is a chronic inflammatory disease,\" he said. <\/p>\n
A biologics license application (BLA) for Dupixent was accepted for Priority Review by the U.S. Food and Drug Administration (FDA) in September 2016. <\/p>\n
(Reporting by Matthias Blamont; writing by John Irish; Editing by Clelia Oziel) <\/p>\n
MAIQUETIA, Venezuela Venezuelan plumber Marcos Heredia scoured 20 pharmacies in one day but could not find crucial medicines to stop his epileptic 8-year-old from convulsions that caused irreparable brain damage late last year. <\/p>\n
(Reuters Health) - - Obese people in the U.S. may not receive the same kind of care at the end of their lives as people who are thin or normal weight, suggests a new study. <\/p>\n
Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer. <\/p>\n
<\/p>\n
See the original post here: PARIS Drugmakers Sanofi and Regeneron said on Saturday results from a one-year test of their Dupixent product aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD) had been positive. \"In the CHRONOS study, Dupixent used with topical corticosteroids showed significantly greater clearance of skin lesions and overall disease severity compared to topical corticosteroids alone, which are commonly prescribed for moderate-to-severe atopic dermatitis,\" Andrew Blauvelt, the principal investigator of the study, said in a joint statement from the companies. \"This study provides positive long-term data for Dupixent, which is important given atopic dermatitis is a chronic inflammatory disease,\" he said Continue reading
\nSanofi, Regeneron say latest Dupixent eczema drug tests positive - Reuters<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"